신증후군 : 시장 인사이트, 역학, 시장 예측(2034년)

Key Highlights:

• The Nephrotic Syndrome market is projected to witness consistent growth throughout the forecast period (2023-2034). The market size of Nephrotic Syndrome in the 7MM is expected to increase, driven by the launch of emerging therapies.
• DelveInsight's analyst projects that among the total diagnosed prevalent cases of Nephrotic Syndrome in 7MM approximately 34% of cases were from the US. As per our estimations, in 2022, the EU4 and the UK accounted for nearly 367 thousand diagnosed prevalent cases of Nephrotic Syndrome.
• In the 7MM, the market mainly consisted of corticosteroids, calcineurin inhibitors, ACE Inhibitors/ARB, immunosuppressant's, and others which generated nearly USD 401 million in 2022.
• The total market size of the Nephrotic Syndrome treatment market is anticipated to experience growth during the forecast period due to the emergence of new and effective treatments, namely, Atacicept, Atrasentan, Gazyva/Gazyvaro (obinutuzumab), Zigakibart (BION-1301), and others.

DelveInsight's "Nephrotic Syndrome - Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Nephrotic Syndrome, historical and forecasted epidemiology and the Nephrotic Syndrome market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The Nephrotic Syndrome market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM Nephrotic Syndrome market size from 2020 to 2034. The report also covers current Nephrotic Syndrome treatment practices/algorithms and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered:

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2020-2034

Disease Understanding and Treatment Algorithm

Nephrotic Syndrome Overview

Nephrotic syndrome is a clinical syndrome defined by massive proteinuria responsible for hypoalbuminemia, with resulting hyperlipidemia, edema, and various complications. Nephrotic syndrome may stem from diverse underlying factors, encompassing conditions like minimal change disease, focal segmental glomerulosclerosis, membranous nephropathy, lupus nephritis, diabetic nephropathy, infections, genetic disorders, specific medications, and more. Prolonged nephrotic syndrome can result in complications such as infections, malnutrition, and an elevated risk of cardiovascular disease. Consequently, accurately pinpointing the precise cause is imperative for effective treatment and comprehensive management.

From a pathological standpoint, nephrotic syndrome entails changes in the structure and function of the glomeruli, which are the small filtration units in the kidneys tasked with eliminating waste and surplus fluids from the blood. The key characteristics of nephrotic syndrome involve heightened permeability of the glomerular filtration barrier, leading to the excretion of proteins, notably albumin, in the urine.

Nephrotic Syndrome Diagnosis

The diagnostic process for nephrotic syndrome encompasses a clinical assessment, blood examinations to evaluate serum albumin and lipid concentrations, urine analyses to detect proteinuria and imaging modalities such as ultrasound. Additionally, a kidney biopsy may be undertaken to pinpoint the root cause, aiding in informed treatment choices. This comprehensive approach ensures a thorough understanding of the condition's nuances, facilitating precise diagnosis and tailored interventions.

Nephrotic Syndrome Treatment

The treatment of nephrotic syndrome involves addressing the fundamental cause and implementing measures to mitigate elevated blood pressure, elevated cholesterol levels, edema, and infection susceptibility. Therapeutic interventions typically comprise medications and dietary modifications. Certain antihypertensive drugs, specifically ACE inhibitors and ARBs, exhibit the potential to decelerate kidney diseases associated with nephrotic syndrome.

Nephrotic Syndrome Epidemiology

As the market is derived using the patient-based model, the Nephrotic Syndrome epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Cases of Nephrotic Syndrome and Type-specific Diagnosed Prevalent Cases of Nephrotic Syndrome, in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan, from 2020 to 2034.

As per DelveInsight's estimations, the total diagnosed prevalent cases of Nephrotic Syndrome in the 7MM were approximately 786 thousand in 2022 and are projected to increase during the forecast period.

• The overall count of individuals diagnosed with Nephrotic Syndrome in the United States was approximately 268 thousand in 2022, and it is expected to increase at an estimated CAGR throughout the study period (2020-2034).
• Among the 7MM, the US accounted for nearly 214 thousand cases of Primary Glomerulonephropathies, and 54 thousand cases of Secondary Glomerulonephropathies. These cases are expected to increase during the forecast period (2023-2034).
• Among EU4 and the UK, Germany had the highest diagnosed prevalent population of Nephrotic Syndrome, with about 98 thousand cases, followed by the UK and France in 2022. On the other hand, Spain had the lowest diagnosed prevalent population in EU4 and the UK in 2022.
• In Japan, there were around 151 thousand diagnosed prevalent cases of Nephrotic Syndrome in 2022. These cases are expected to decrease by 2034.

Nephrotic Syndrome Drug Chapters

The drug chapter segment of the Nephrotic Syndrome report encloses a detailed analysis of Nephrotic Syndrome marketed drugs and late-stage (Phase III and Phase II) pipeline drugs. It also understands Nephrotic Syndrome clinical trial details, expressive pharmacological action, agreements and collaborations, approval, and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Emerging Drugs

Atacicept: Vera Therapeutics

Atacicept developed by Vera Therapeutics, is an investigational recombinant fusion protein that contains the soluble transmembrane activator and calcium-modulating cyclophilin ligand interactor (TACI) receptor that binds to the cytokines B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL). These cytokines are members of the tumor necrosis factor family that promote B-cell survival and autoantibody production associated with certain autoimmune diseases, including IgA nephropathy and lupus nephritis.

Atrasentan: Chinook Therapeutics/ Novartis

Atrasentan is an oral potent and selective endothelin A (ETA) receptor antagonist, which works by inhibiting the ETA receptor activation of multiple renal cell types. This blockade reduces kidney inflammation and fibrosis, thus leading to reduced proteinuria in patients with chronic kidney disease.

Note: Detailed emerging therapies assessment will be provided in the final report of Nephrotic Syndrome.

Nephrotic Syndrome Market Outlook

Nephrotic syndrome is a collection of symptoms that signal impaired kidney function. These symptoms encompass proteinuria, hypoalbuminemia, edema, hyperlipidemia, and various other associated complications.

The management of nephrotic syndrome entails addressing underlying medical conditions contributing to its onset. Healthcare professionals may prescribe medications and dietary modifications to regulate symptoms and address complications associated with nephrotic syndrome. Currently, there are no authorized therapies specifically designed for treating nephrotic syndrome, and the predominant treatment strategies often involve off-label approaches. Corticosteroids like prednisone, cyclophosphamide, and cyclosporine are employed to induce remission in nephrotic syndrome. Diuretics are utilized to alleviate edema, while angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers are employed to diminish proteinuria.

Progress in the treatment of nephrotic syndrome has transformed patient care, integrating lifestyle modifications, medications, and procedures. Emerging therapies, including monoclonal antibodies and antagonists targeting APRIL and BAFF, among others, hold the potential for improving patient outcomes. Continuous research and ongoing clinical trials are shaping a promising future for nephrotic syndrome treatment, providing optimism for a world with decreased morbidity and mortality.

The market for Nephrotic Syndrome is expected to experience positive growth with the approval of potential drugs like Atacicept, Atrasentan, Gazyva/Gazyvaro (obinutuzumab), Zigakibart (BION-1301), and others.

• The Nephrotic Syndrome market's total size in the 7MM reached approximately USD 401 million in 2022. Projections indicate a substantial growth during the forecast period.
• Out of the 7MM, the United States dominated the market in 2022, representing the largest share at nearly 50%.
• In 2022, EU4 and the UK captured an estimated USD 137 million, which is anticipated to increase at a substantial CAGR. Among the European countries, Germany covered the largest market share in 2022, followed by the UK, France, and Italy. Spain accounted for the least market in the same year.
• Japan alone represented approximately 16% of the total Nephrotic Syndrome market in 2022, projected to increase at a substantial CAGR during the study period.
• The total market size of the Nephrotic Syndrome treatment market is anticipated to experience growth during the forecast period due to the emergence of new and effective treatments.

Nephrotic Syndrome Drugs Uptake

This section focuses on the uptake rate of potential drugs expected to launch in the market during 2020-2034. For example, Atacicept in the US is expected to be launched by 2027.

Further detailed analysis of emerging therapies drug uptake in the report…

Nephrotic Syndrome Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, Phase II, and Phase I stage. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for Nephrotic Syndrome emerging therapies.

KOL Views

To keep up with current market trends, we take KOLs and SMEs' opinions working in the domain through primary research to fill the data gaps and validate the secondary research. Industry Experts were contacted for insights on Nephrotic Syndrome evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake along with challenges related to accessibility, including KOL from Boston Children's Hospital, Ohio State University, Montefiore Medical Center, Hannover Medical School, Hannover, Hopital Robert-Debre, APHP, Paris, Istituto G. Gaslini, Genoa, Hospital Universitario Fundacion Jimenez Diaz, UCL Department of Renal Medicine, National Health Service, England, Fukushima Medical University, Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Ibaraki, Japan, and others.

Delveinsight's analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Their opinion helps understand and validate current and emerging therapies, treatment patterns, or Nephrotic Syndrome market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Qualitative Analysis

We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst's discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.

Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

Further, the therapies' safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the route of administration, order of entry and designation, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Market Access and Reimbursement

The high cost of therapies for the treatment is a major factor restraining the growth of the global drug market. Because of the high cost, the economic burden is increasing, leading the patient to escape from proper treatment.

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Scope of the Report:

• The report covers a segment of key events, an executive summary, descriptive overview of Nephrotic Syndrome, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and treatment guidelines.
• Additionally, an all-inclusive account of the current and emerging therapies and the elaborative profiles of late-stage and prominent therapies will impact the current treatment landscape.
• A detailed review of the Nephrotic Syndrome market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind the approach is included in the report covering the 7MM drug outreach.
• The report provides an edge while developing business strategies, by understanding trends, through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help shape and drive the 7MM Nephrotic Syndrome market.

Nephrotic Syndrome Report Insights

• Patient Population
• Therapeutic Approaches
• Nephrotic Syndrome Pipeline Analysis
• Nephrotic Syndrome Market Size and Trends
• Existing and Future Market Opportunity

Nephrotic Syndrome Report Key Strengths

• 12 years Forecast
• The 7MM Coverage
• Nephrotic Syndrome Epidemiology Segmentation
• Key Cross Competition
• Conjoint Analysis
• Drugs Uptake and Key Market Forecast Assumptions

Nephrotic Syndrome Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Qualitative Analysis (SWOT and Conjoint Analysis)

Key Questions:

Market Insights

• What was the Nephrotic Syndrome total market size, the market size by therapies, and market share (%) distribution in 2020, and how would it all look in 2034? What are the contributing factors for this growth?
• What unmet needs are associated with the current treatment market of Nephrotic Syndrome?
• What are the patents of emerging therapies for Nephrotic Syndrome?
• Which drug is going to be the largest contributor by 2034?
• What are the pricing variations among different geographies for approved and off-label therapies?
• How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights

• What are the disease risks, burdens, and unmet needs of Nephrotic Syndrome? What will be the growth opportunities across the 7MM concerning the patient population of Nephrotic Syndrome?
• What is the historical and forecasted Nephrotic Syndrome patient pool in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan?
• Why do only limited patients appear for diagnosis?
• Which country is more prevalent for Nephrotic Syndrome and why?
• What factors are affecting the diagnosis of the indication?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies

• What are the current options for treating Nephrotic Syndrome? What are the current guidelines for treating Nephrotic Syndrome in the US and Europe?
• How many companies are developing therapies for treating Nephrotic Syndrome?
• How many emerging therapies are in the mid-stage and late stage of development for treating Nephrotic Syndrome?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitations of existing therapies?
• What are the key designations that have been granted for the emerging therapies for Nephrotic Syndrome?
• Patient acceptability in terms of preferred treatment options as per real-world scenarios?
• What are the country-specific accessibility issues of expensive, recently approved therapies? Focus on reimbursement policies.
• What are the 7MM historical and forecasted markets of Nephrotic Syndrome?

Reasons to Buy:

• The report will help develop business strategies by understanding the latest trends and changing treatment dynamics driving the Nephrotic Syndrome Market.
• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand the existing market opportunity in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Identifying strong upcoming players in the market will help devise strategies that will help get ahead of competitors.
• Detailed analysis and ranking of potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• Highlights of Access and Reimbursement policies of approved therapies, barriers to accessibility of off-label expensive therapies, and patient assistance programs.
• To understand the perspective of Key Opinion Leaders around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.

Frequently Asked Questions

1. What is the forecast period covered in the report?

• The Nephrotic Syndrome Epidemiology and Market Insight report for the 7MM covers the forecast period from 2023 to 2034, providing a projection of market dynamics and trends during this timeframe.

2. Who are the key players in the Nephrotic Syndrome market?

• The Nephrotic Syndrome emerging market many drugs. The major key players developing therapies for Nephrotic Syndrome are Vera Therapeutics, Novartis, Chinook Therapeutics, AstraZeneca, Hoffmann-La Roche, Otsuka Pharmaceutical Development and Commercialization, Visterra and others.

3. How is the market size estimated in the forecast report?

• The market size is estimated through data analysis, statistical modeling, and expert opinions. It may consider factors such as prevalent cases, treatment costs, revenue generated, and market trends.

4. What is the key driver of the Nephrotic Syndrome market?

• The increase in diagnosed prevalent cases of Nephrotic Syndrome and the launch of emerging therapies are attributed to be the key drivers for increasing Nephrotic Syndrome market.

5. What is the expected impact of emerging therapies or advancements in Nephrotic Syndrome treatment on the market?

• Introducing new therapies, advancements in disease understanding and diagnostic techniques, and innovations in treatment approaches can significantly impact the Nephrotic Syndrome treatment market. Market forecast reports may provide analysis and predictions regarding the potential impact of these developments.

6. Does the report provide insights into the competitive landscape of the market?

• The market forecast report may include information on the competitive landscape, profiling key market players, their product offerings, partnerships, and strategies, and helping stakeholders understand the competitive dynamics of the Nephrotic Syndrome market.

Table of Contents

1. Key Insights

2. Report Introduction

3. Nephrotic Syndrome Market Overview at a Glance

• 3.1. Market Share (%) Distribution of Nephrotic Syndrome by Therapies in 2020
• 3.2. Market Share (%) Distribution of Nephrotic Syndrome by Therapies in 2034

4. Epidemiology and Market Methodology of Nephrotic Syndrome

5. Executive Summary of Nephrotic Syndrome

6. Key Events

7. Nephrotic Syndrome: Disease Background and Overview

• 7.1. Introduction
• 7.2. Etiology
• 7.3. Clinical Manifestation
• 7.4. Complications
• 7.5. Pathophysiology
• 7.6. Diagnosis
  • 7.6.1. Differential Diagnosis
  • 7.6.2. Diagnostic Algorithm
• 7.7. Management and Treatment
  • 7.7.1. Treatment Algorithm
• 7.8. Guidelines
  • 7.8.1. Diagnosis and Management of Nephrotic Syndrome in Adults: American Family Physician (2016)
  • 7.8.2. International Pediatric Nephrology Association (IPNA) Clinical Practice Recommendations for the Diagnosis and Management of Children with Steroid-resistant Nephrotic Syndrome (2022)
  • 7.8.3. Clinical Practice Guidelines for Nephrotic Syndrome (2022)
  • 7.8.4. Management of Childhood Onset Nephrotic Syndrome: The American Academy of Pediatrics (AAP)
  • 7.8.5. Clinical Commissioning Policy: National Health Service (NHS)
  • 7.8.6. Evidence-Based Clinical Practice Guidelines for Nephrotic Syndrome (2014)
  • 7.8.7. International Society of Nephrology: Kidney Disease Improving Global Outcomes (KDIGO), 2012
  • 7.8.8. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases

8. Epidemiology and Patient Population

• 8.1. Key Findings
• 8.2. Assumptions and Rationale: The 7MM
  • 8.2.1. FSGS
  • 8.2.2. IgA Nephropathy
  • 8.2.3. Membranous Nephropathy
  • 8.2.4. Others
• 8.3. Total Diagnosed Prevalent Cases of Nephrotic Syndrome in the 7MM
• 8.4. The United States
  • 8.4.1. Total Diagnosed Prevalent Cases of Nephrotic Syndrome in the United States
  • 8.4.2. Type-specific Diagnosed Prevalent Cases of Nephrotic Syndrome in the United States
• 8.5. EU4 and the UK
  • 8.5.1. Total Diagnosed Prevalent Cases of Nephrotic Syndrome in EU4 and the UK
  • 8.5.2. Type-specific Diagnosed Prevalent Cases of Nephrotic Syndrome in EU4 and the UK
• 8.6. Japan
  • 8.6.1. Total Diagnosed Prevalent Cases of Nephrotic Syndrome in Japan
  • 8.6.2. Type-specific Diagnosed Prevalent Cases of Nephrotic Syndrome in Japan

9. Patient Journey

10. Marketed Drugs

• 10.1. Key Competitors
• 10.2. LUPKYNIS (voclosporin): Aurinia Pharmaceuticals/Otsuka Pharmaceutical
  • 10.2.1. Product Description
  • 10.2.2. Regulatory Milestones
  • 10.2.3. Other Developmental Activities
  • 10.2.4. Clinical Development
  • 10.2.5. Clinical Trials Information
  • 10.2.6. Safety and Efficacy
  • 10.2.7. Product Profile
• 10.3. BENLYSTA (belimumab): GSK
  • 10.3.1. Product Description
  • 10.3.2. Regulatory Milestones
  • 10.3.3. Clinical Development
  • 10.3.4. Clinical Trials Information
  • 10.3.5. Safety and Efficacy
  • 10.3.6. Product Profile
• 10.4. INVOKANA (Canagliflozin): Johnson & Johnson
  • 10.4.1. Product Description
  • 10.4.2. Regulatory Milestones
  • 10.4.3. Other Developmental Activities
  • 10.4.4. Clinical Development
  • 10.4.5. Clinical Trials Information
  • 10.4.6. Safety and Efficacy
  • 10.4.7. Product Profile
• 10.5. FILSPARI (Sparsentan): Travere Therapeutics/CSL Vifor
  • 10.5.1. Product Description
  • 10.5.2. Regulatory Milestones
  • 10.5.3. Other Developmental Activities
  • 10.5.4. Clinical Development
  • 10.5.5. Clinical Trials Information
  • 10.5.6. Safety and Efficacy
  • 10.5.7. Product Profile
• 10.6. TARPEYO (budesonide): Calliditas Therapeutics AB
  • 10.6.1. Product Description
  • 10.6.2. Regulatory Milestones
  • 10.6.3. Other Developmental Activities
  • 10.6.4. Clinical Development
  • 10.6.5. Clinical Trials Information
  • 10.6.6. Safety and Efficacy
  • 10.6.7. Product Profile

11. Emerging Therapies

• 11.1. Key Cross Competition
• 11.2. Inaxaplin (VX-147): Vertex Pharmaceuticals
  • 11.2.1. Product Description
  • 11.2.2. Other Development Activities
  • 11.2.3. Clinical Development
  • 11.2.4. Clinical Trials Information
  • 11.2.5. Safety and Efficacy
  • 11.2.6. Product Profile
  • 11.2.7. Analysts' Views
• 11.3. Atrasentan: Chinook Therapeutics/ Novartis
  • 11.3.1. Product Description
  • 11.3.2. Other Development Activities
  • 11.3.3. Clinical Development
  • 11.3.4. Clinical Trials Information
  • 11.3.5. Safety and Efficacy
  • 11.3.6. Product Profile
  • 11.3.7. Analysts' Views
• 11.4. BI 764198: Boehringer Ingelheim
  • 11.4.1. Product Description
  • 11.4.2. Clinical Development
  • 11.4.3. Clinical Trials Information
  • 11.4.4. Product Profile
  • 11.4.5. Analysts' Views
• 11.5. Obinutuzumab (RG7159, GA101): Hoffmann-La Roche/Biogen
  • 11.5.1. Product Description
  • 11.5.2. Other Development Activities
  • 11.5.3. Clinical Development
  • 11.5.4. Clinical Trials Information
  • 11.5.5. Safety and Efficacy
  • 11.5.6. Product Profile
  • 11.5.7. Analysts' Views
• 11.6. SNP-ACTH (1-39) Gel: Cerium Pharmaceuticals
  • 11.6.1. Product Description
  • 11.6.2. Other Development Activities
  • 11.6.3. Clinical Development
  • 11.6.4. Clinical Trials Information
  • 11.6.5. Safety and Efficacy
  • 11.6.6. Product Profile
  • 11.6.7. Analysts' Views
• 11.7. VIS649 (sibeprenlimab): Otsuka Pharmaceutical Development & Commercialization/Visterra
  • 11.7.1. Product Description
  • 11.7.2. Other Development Activities
  • 11.7.3. Clinical Development
  • 11.7.4. Clinical Trials Information
  • 11.7.5. Safety and Efficacy
  • 11.7.6. Product Profile
  • 11.7.7. Analysts' Views
• 11.8. ASO factor B (IONIS-FB-LRx, RG6299): Hoffmann-La Roche/Ionis Pharmaceuticals
  • 11.8.1. Product Description
  • 11.8.2. Other Development Activities
  • 11.8.3. Clinical Development
  • 11.8.4. Clinical Trials Information
  • 11.8.5. Safety and Efficacy
  • 11.8.6. Product Profile
  • 11.8.7. Analysts' Views
• 11.9. Ianalumab (VAY736): Novartis
  • 11.9.1. Product Description
  • 11.9.2. Clinical Development
  • 11.9.3. Clinical Trials Information
  • 11.9.4. Safety and Efficacy
  • 11.9.5. Product Profile
  • 11.9.6. Analysts' Views
• 11.1. Zetomipzomib (KZR-616): Kezar Life Sciences
  • 11.10.1. Product Description
  • 11.10.2. Other Development Activities
  • 11.10.3. Clinical Development
  • 11.10.4. Clinical Trials Information
  • 11.10.5. Safety and Efficacy
  • 11.10.6. Product Profile
  • 11.10.7. Analysts' Views
• 11.11. Povetacicept (ALPN-303): Alpine Immune Sciences
  • 11.11.1. Product Description
  • 11.11.2. Other Development Activities
  • 11.11.3. Clinical Development
  • 11.11.4. Clinical Trials Information
  • 11.11.5. Safety and Efficacy
  • 11.11.6. Product Profile
  • 11.11.7. Analysts' Views
• 11.12. DMX-200: Dimerix Bioscience/Advanz Pharma
  • 11.12.1. Product Description
  • 11.12.2. Other Development Activities
  • 11.12.3. Clinical Development
  • 11.12.4. Clinical Trials Information
  • 11.12.5. Safety and Efficacy
  • 11.12.6. Product Profile
  • 11.12.7. Analyst Views
• 11.13. EMPAVELI (pegcetacoplan): Apellis Pharmaceuticals
  • 11.13.1. Product Description
  • 11.13.2. Other Developmental Activities
  • 11.13.3. Clinical Development
  • 11.13.4. Clinical Trials Information
  • 11.13.5. Safety and Efficacy
  • 11.13.6. Product Profile
  • 11.13.7. Analyst Views
• 11.14. LNP023 (iptacopan): Novartis Pharmaceuticals
  • 11.14.1. Product Description
  • 11.14.2. Other Developmental Activities
  • 11.14.3. Clinical Development
  • 11.14.4. Clinical Trials Information
  • 11.14.5. Safety and Efficacy
  • 11.14.6. Product Profile
  • 11.14.7. Analyst Views
• 11.15. Zigakibart (BION-1301): Chinook Therapeutics, Inc./Novartis
  • 11.15.1. Product Description
  • 11.15.2. Other Developmental Activities
  • 11.15.3. Clinical Development
  • 11.15.4. Clinical Trials Information
  • 11.15.5. Safety and Efficacy
  • 11.15.6. Product Profile
  • 11.15.7. Analyst Views
• 11.16. Atacicept: Vera Therapeutics, Inc.
  • 11.16.1. Product Description
  • 11.16.2. Other Developmental Activities
  • 11.16.3. Clinical Development
  • 11.16.4. Clinical Trials Information
  • 11.16.5. Safety and Efficacy
  • 11.16.6. Product Profile
  • 11.16.7. Analyst Views
• 11.17. Saphnelo (anifrolumab): AstraZeneca
  • 11.17.1. Product Description
  • 11.17.2. Clinical Development
  • 11.17.3. Clinical Trials Information
  • 11.17.4. Safety and Efficacy
  • 11.17.5. Product Profile
  • 11.17.6. Analyst Views
• 11.18. Felzartamab (MOR202): HI-Bio
  • 11.18.1. Product Description
  • 11.18.2. Other Developmental Activities
  • 11.18.3. Clinical Development
  • 11.18.4. Clinical Trials Information
  • 11.18.5. Safety and Efficacy
  • 11.18.6. Product Profile
  • 11.18.7. Analyst Views

12. Nephrotic Syndrome: Seven Major Market Analysis

• 12.1. Key Findings: Market
• 12.2. Key Market Forecast Assumptions
• 12.3. Conjoint Analysis
• 12.4. Market Outlook
• 12.5. Market Size of Nephrotic Syndrome in the 7MM
• 12.6. Market size of Nephrotic Syndrome by Therapies in the 7MM
• 12.7. Market Size of Nephrotic Syndrome in the United States
  • 12.7.1. Total Market Size of Nephrotic Syndrome
  • 12.7.2. Market Size of Nephrotic Syndrome by Therapies
• 12.8. Market Size of Nephrotic Syndrome in EU4 and the UK
  • 12.8.1. Total Market Size of Nephrotic Syndrome in EU4 and the UK
  • 12.8.2. Market Size of Nephrotic Syndrome by Therapies
• 12.9. Market Size of Nephrotic Syndrome in Japan
  • 12.9.1. Total Market Size of Nephrotic Syndrome in Japan
  • 12.9.2. Market Size of Nephrotic Syndrome by Therapies

13. KOL Views

14. SWOT Analysis

15. Unmet Needs

16. Market Access and Reimbursement

• 16.1. The United States
  • 16.1.1. Center for Medicare & Medicaid Services (CMS)
• 16.2. In EU4 and the UK
  • 16.2.1. Germany
  • 16.2.2. France
  • 16.2.3. Italy
  • 16.2.4. Spain
  • 16.2.5. The United Kingdom
• 16.3. Japan
  • 16.3.1. MHLW

17. Appendix

• 17.1. Bibliography
• 17.2. Acronyms and Abbreviations
• 17.3. Report Methodology

18. DelveInsight Capabilities

19. Disclaimer